Search
for
Sort by
Research 30 of 1000+
- Assessing the real-world safety of tralokinumab for atopic dermatitis: insights from a comprehensive analysis of FAERS data
- Assessing finasteride-associated sexual dysfunction using the FAERS database
- Adverse events associated with vismodegib: insights from a real-world pharmacovigilance study using the FAERS database
- Evaluation of dermatologic adverse events associated with aromatase inhibitors: insights from the FAERS database
- (719) Signal Detection of Depression and Suicidality With the 5-Alpha Reductase Inhibitors: Evidence from the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) Database
- Cardiovascular Safety Signals of Oral Versus Topical Minoxidil in FAERS: A Disproportionality Analysis (Analytic Cohort 2012–2025)
- Comparative safety profiles of baricitinib and tofacitinib in the treatment of adult alopecia areata: a pharmacovigilance study based on the FAERS database
- Drug related lipid metabolism abnormalities: a real-world pharmacovigilance exploratory analysis based on U.S. FDA adverse event reporting system (FAERS)
- Multidimensional assessment of adverse events of finasteride：a real-world pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS) from 2004 to April 2024
- Multidimensional assessment of adverse events of finasteride:a real-world pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS) from 2004 to April 2024
- Agglomerative clustering-based drugs graded for the risk signals of drug-induced cognitive disorder: a study on the FAERS database
- Case Report: Omalizumab-associated hair loss: a case of eyebrow alopecia areata, literature review and FAERS database analysis
- Assessing finasteride-associated sexual dysfunction using the FAERS database
- A Review of the FAERS Data on 5-Alpha Reductase Inhibitors: Implications for Postfinasteride Syndrome
- Drug-induced vitiligo: a real-world pharmacovigilance analysis of the FAERS database
- Risk of Autoimmune Skin Diseases Associated With Immune Checkpoint Inhibitors: A Pharmacovigilance Analysis Using the FAERS Database
- Re: A Review of the FAERS Data on 5-Alpha Reductase Inhibitors: Implications for Post-Finasteride Syndrome
- Drug-induced male infertility: a real-world study using FAERS and EudraVigilance databases
- Abstract 4142154: Risk of Suicide, Hair Loss, and Aspiration with Glucagon-like Peptide 1 Receptor Agonists: A Real-World Pharmacovigilance Study from the FAERS database
- Adverse events with finasteride or dutasteride: FAERS
- Epidemiology, clinical features, and outcome of the hospitalized patients with Kerion in Fars Province, Iran: an eleven-year retrospective study
- Analyzing real-world adverse events of spironolactone with the FAERS database
- Assessing the safety of topical minoxidil through disproportionality analysis of FAERS reports
- Low‐Dose Oral Minoxidil and Associated Adverse Events: Analyses of the FDA Adverse Event Reporting System (FAERS) With a Focus on Pericardial Effusions
- Post-marketing safety signals of four JAK inhibitors for alopecia areata: an indication-restricted FAERS pharmacovigilance study
- Mining and analysis of adverse event signals of isotretinoin based on the real-world data of FAERS database
- Disproportionality analysis comparing safety profiles of sonidegib and vismodegib based on the FAERS database
- The pharmacovigilance analysis of adverse events of erlotinib based on the open access FAERS database
- Investigating tralokinumab-related adverse events in treating atopic dermatitis: insights from the FAERS database
- Safety Assessment of Ritlecitinib Based on the FDA Adverse Event Reporting System (FAERS) Database: A Real‐World Pharmacovigilance Study